Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions

J Am Coll Cardiol. 2004 Jul 21;44(2):316-23. doi: 10.1016/j.jacc.2004.02.059.

Abstract

Objectives: We examined the lytic effects of anti-glycoprotein (GP) IIb/IIIa agents on platelet thrombi formed on the collagen surface under blood flow conditions.

Background: Anti-GP IIb/IIIa agents may influence platelet thrombi already formed.

Methods: Blood samples were anticoagulated either by the specific antithrombin Argatroban (100 microM) or by unfractionated heparin (0.1 U/ml). After platelet thrombi were formed on a collagen surface following 6-min perfusion of whole blood obtained from eight adult donors containing fluorescinated platelets at a wall shear rate of 1,500 s(-1), additional blood samples from the same donors either containing or not containing anti-GP IIb/IIIa agents (abciximab, eptifibatide, or tirofiban) were perfused on these thrombi. The three-dimensional structures of the platelet thrombi were continuously observed by laser confocal microscopy equipped with a piezo-electric motor control unit and recorded.

Results: The platelet thrombi started to dissolve after perfusion of blood containing the anti-GP IIb/IIIa agents, whereas their growth resumed after subsequent perfusion of control blood. Only a single layer of platelets having heights of 3 +/- 1 microm, 3 +/- 2 microm, and 3 +/- 1 microm, respectively, could be seen after 6-min perfusion of blood containing abciximab, eptifibatide, and tirofiban, whereas the initial height of the platelet thrombi of 8 +/- 2 microm increased to 11 +/- 4 microm after subsequent perfusion of control blood (n = 8). The volume of the platelet thrombi, which was 3,352 +/- 1,045 microm(3) before starting the second perfusion, was reduced to 778 +/- 102 microm(3), 812 +/- 122 microm(3), and 856 +/- 144 microm(3) after 6-min perfusion of blood containing abciximab, eptifibatide, and tirofiban, respectively.

Conclusions: We have shown in this study that anti-GP IIb/IIIa agents possess the ability to dissolve platelet thrombi.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abciximab
  • Adult
  • Antibodies, Monoclonal / pharmacology
  • Anticoagulants / pharmacology
  • Arginine / analogs & derivatives
  • Blood Platelets / drug effects
  • Blood Platelets / physiology*
  • Collagen
  • Eptifibatide
  • Fibrinolytic Agents / pharmacology*
  • Hemorheology
  • Humans
  • Immunoglobulin Fab Fragments / pharmacology
  • In Vitro Techniques
  • Peptides / pharmacology
  • Pipecolic Acids / pharmacology
  • Platelet Aggregation / drug effects
  • Platelet Aggregation Inhibitors / pharmacology*
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
  • Sulfonamides
  • Thrombosis / physiopathology*
  • Thrombosis / therapy
  • Tirofiban
  • Tyrosine / analogs & derivatives*
  • Tyrosine / pharmacology

Substances

  • Antibodies, Monoclonal
  • Anticoagulants
  • Fibrinolytic Agents
  • Immunoglobulin Fab Fragments
  • Peptides
  • Pipecolic Acids
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Sulfonamides
  • Tyrosine
  • Collagen
  • Arginine
  • Tirofiban
  • argatroban
  • Eptifibatide
  • Abciximab